Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890986664> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2890986664 abstract "11546 Background: TRC105, an endoglin-targeting monoclonal antibody with anti-angiogenic and anti-tumor activity, is being evaluated in multiple diseases. Here we report on pharmacodynamic and prognostic biomarkers in patients (pts) treated with both TRC105 and anti-VEGF agents. Methods: Plasma samples were collected from pts on three phase 2 trials combining TRC105 with an anti-VEGF agent: axitinib in metastatic renal cell carcinoma (mRCC), pazopanib in advanced soft tissue sarcoma, and bevacizumab in glioblastoma (GBM). Baseline and on-treatment levels of 22 soluble protein biomarkers were assessed. Results: Soluble endoglin markedly increased after TRC105 treatment in all pts ( p< 0.001) as previously reported. BMP9 (a ligand for endoglin) and TGFβR3 (a type III TGFβ receptor) decreased in sarcoma pts at Cycle 2 Day 1 (C2D1) and generally remained below baseline throughout the course of treatment (BMP9, p= 0.004; TGFβR3, p= 0.003). Although TGFβR3 was decreased at C2D1 in mRCC (p = 0.030), no clear patterns were observed over time. Overall BMP9 levels did not change in response to therapy in either mRCC or GBM. Osteopontin (OPN) levels, a downstream effector of TGFβ signaling, were increased in sarcoma pts [ p= 0.002 at C2D15, p< 0.001 at C4D1 and end of study (EOS)]; however, in mRCC ( p= 0.010) and GBM ( p= 0.003), OPN was only elevated at EOS. Increases in PlGF and VEGFD, and decreases in VEGFR2 were observed across all studies, as previously noted for VEGF inhibitors. In the mRCC trial, 5 of 18 pts exhibited a ≥30% tumor reduction. Lower OPN ( p= 0.026) and higher TGFβR3 ( p= 0.003) levels at baseline correlated with radiographic response to treatment. In the sarcoma trial, 6 of 19 pts responded (CHOI criteria) in which lower baseline levels of ICAM1 ( p= 0.018) and TSP2 ( p= 0.042) correlated with stable disease. Conclusions: In these trials, increases of soluble endoglin in response to TRC105 were observed, independent of the presence of any specific VEGF inhibitor. Differential regulation of BMP9, TGFβR3, and OPN suggests potential disease-specific modulation of key TGFβ signaling molecules in response to dual therapy. Baseline levels of OPN and TGFβR3 showed potential prognostic value in mRCC. Confirmation in larger trials is needed." @default.
- W2890986664 created "2018-09-27" @default.
- W2890986664 creator A5005702417 @default.
- W2890986664 creator A5015379338 @default.
- W2890986664 creator A5031078301 @default.
- W2890986664 creator A5035978871 @default.
- W2890986664 creator A5037380551 @default.
- W2890986664 creator A5038983454 @default.
- W2890986664 creator A5044586794 @default.
- W2890986664 creator A5046311492 @default.
- W2890986664 creator A5049193088 @default.
- W2890986664 creator A5052504518 @default.
- W2890986664 creator A5056823515 @default.
- W2890986664 creator A5061366384 @default.
- W2890986664 creator A5062010101 @default.
- W2890986664 creator A5086993471 @default.
- W2890986664 date "2017-05-20" @default.
- W2890986664 modified "2023-09-29" @default.
- W2890986664 title "Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy." @default.
- W2890986664 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.11546" @default.
- W2890986664 hasPublicationYear "2017" @default.
- W2890986664 type Work @default.
- W2890986664 sameAs 2890986664 @default.
- W2890986664 citedByCount "1" @default.
- W2890986664 countsByYear W28909866642018 @default.
- W2890986664 crossrefType "journal-article" @default.
- W2890986664 hasAuthorship W2890986664A5005702417 @default.
- W2890986664 hasAuthorship W2890986664A5015379338 @default.
- W2890986664 hasAuthorship W2890986664A5031078301 @default.
- W2890986664 hasAuthorship W2890986664A5035978871 @default.
- W2890986664 hasAuthorship W2890986664A5037380551 @default.
- W2890986664 hasAuthorship W2890986664A5038983454 @default.
- W2890986664 hasAuthorship W2890986664A5044586794 @default.
- W2890986664 hasAuthorship W2890986664A5046311492 @default.
- W2890986664 hasAuthorship W2890986664A5049193088 @default.
- W2890986664 hasAuthorship W2890986664A5052504518 @default.
- W2890986664 hasAuthorship W2890986664A5056823515 @default.
- W2890986664 hasAuthorship W2890986664A5061366384 @default.
- W2890986664 hasAuthorship W2890986664A5062010101 @default.
- W2890986664 hasAuthorship W2890986664A5086993471 @default.
- W2890986664 hasConcept C126322002 @default.
- W2890986664 hasConcept C143998085 @default.
- W2890986664 hasConcept C167734588 @default.
- W2890986664 hasConcept C185592680 @default.
- W2890986664 hasConcept C2781197716 @default.
- W2890986664 hasConcept C502942594 @default.
- W2890986664 hasConcept C55493867 @default.
- W2890986664 hasConcept C71924100 @default.
- W2890986664 hasConceptScore W2890986664C126322002 @default.
- W2890986664 hasConceptScore W2890986664C143998085 @default.
- W2890986664 hasConceptScore W2890986664C167734588 @default.
- W2890986664 hasConceptScore W2890986664C185592680 @default.
- W2890986664 hasConceptScore W2890986664C2781197716 @default.
- W2890986664 hasConceptScore W2890986664C502942594 @default.
- W2890986664 hasConceptScore W2890986664C55493867 @default.
- W2890986664 hasConceptScore W2890986664C71924100 @default.
- W2890986664 hasLocation W28909866641 @default.
- W2890986664 hasOpenAccess W2890986664 @default.
- W2890986664 hasPrimaryLocation W28909866641 @default.
- W2890986664 hasRelatedWork W2016898759 @default.
- W2890986664 hasRelatedWork W2039548371 @default.
- W2890986664 hasRelatedWork W2252538984 @default.
- W2890986664 hasRelatedWork W2278052588 @default.
- W2890986664 hasRelatedWork W2498724526 @default.
- W2890986664 hasRelatedWork W2503346361 @default.
- W2890986664 hasRelatedWork W2741591300 @default.
- W2890986664 hasRelatedWork W2795707606 @default.
- W2890986664 hasRelatedWork W2945529338 @default.
- W2890986664 hasRelatedWork W3030631608 @default.
- W2890986664 hasRelatedWork W3117456670 @default.
- W2890986664 hasRelatedWork W3121630953 @default.
- W2890986664 hasRelatedWork W2292038304 @default.
- W2890986664 hasRelatedWork W2753362971 @default.
- W2890986664 hasRelatedWork W2756747962 @default.
- W2890986664 hasRelatedWork W2814751924 @default.
- W2890986664 hasRelatedWork W2815193680 @default.
- W2890986664 hasRelatedWork W2924731427 @default.
- W2890986664 hasRelatedWork W2930508830 @default.
- W2890986664 hasRelatedWork W2985632053 @default.
- W2890986664 isParatext "false" @default.
- W2890986664 isRetracted "false" @default.
- W2890986664 magId "2890986664" @default.
- W2890986664 workType "article" @default.